Senses Disorder TRIZ Cases

Cell-permeable reversible succinate dehydrogenase inhibitors prevent permanent enzyme inactivation while reducing reperfusion injury.

A stable ophthalmic formulation combines Dorzolamide, Timolol, and Brimonidine using specific excipients to maintain active ingredient concentrations.

Selective azetidine 2-carboxamide derivatives target the CB2 receptor to reduce inflammation and pain without triggering psychoactive side effects.

Antibodies bind specifically to laminin alpha 4 LG4-5 modules, inhibiting angiogenesis and reducing chemotherapy side effects.

Sodium thiosulfate sequesters platinum agents to prevent irreversible hearing loss while maintaining chemotherapy efficacy.

Fluorescent markers enable precise detection of blinding eye diseases through near-infrared imaging, addressing inadequate diagnostic capabilities.

Mutated neurturin polypeptides reduce heparin binding affinity to enable broader brain tissue diffusion.

A salivary-producing lollipop generates negative pressure in the oral cavity to facilitate fluid drainage from Eustachian tubes.

Formula I compounds inhibit MetAP-2, improving efficacy while reducing tolerability issues in cancer therapy.

A herbal composition manages cough symptoms through synergistic antitussive and expectorant actions.

Topical anti-angiogenic compounds replace invasive injections with eye drops, reducing treatment complexity and cost.

Indolizine derivatives antagonize the P2X7 receptor, reducing CNS inflammation and providing neuroprotection for multiple sclerosis and Alzheimer's disease.

Enzymatic segmentation isolates bioactive glycans from edible bird's nest, resolving low bioavailability and allergenicity.

Stable liposomes carry anti-VEGF antibodies through the cornea to the vitreous cavity, reducing intravitreal injection risks.

Janus kinase inhibitors block inflammatory signaling pathways to treat dry eye syndrome.

8-Oxo-2'-deoxyguanosine inhibits inflammation and neovascularization to restore corneal clarity.

Anti-CSF1R antibodies reduce fibrosis obstacles that limit anti-VEGF therapy efficacy, improving treatment reliability for ocular conditions.

Recombinant fusion protein combines anti-PD-L1 antibody with VEGF binding peptide to enable simultaneous target engagement.

Stem cell differentiation protocol enriches functional photoreceptors for retinal disease therapy.

Topical oxymetazoline hydrochloride accelerates wound healing by reducing epidermal necrosis and minimizing scar formation through targeted vasoconstriction.

Oral Enterococcus faecium strains alleviate Th17 inflammatory reactions by lowering IL-17 levels, addressing limited therapeutic options.

Sweet potato stem extract treats hearing loss and tinnitus without antibiotic ototoxicity.

A sealed tray kit reconstitutes mitomycin-C powder using a syringe and diluent carrier to draw the solution into absorbent pads.

Combining nitazoxanide with statins inhibits myofibroblast activation and reduces bile acid concentrations.

A folate composition treats ocular diseases linked to elevated retinal venous pressure.

Albumin nanoparticles deliver monoclonal antibodies via diffusion and erosion, eliminating repetitive injections that cause patient discomfort.

Topical SOCS1-derived peptides inhibit JAK2 kinase activity, reducing glial activation and blood-retinal barrier disruption while preventing neurodegeneration.

Esterified pyridine salts enhance MNA bioavailability by overcoming rapid renal elimination through controlled in vivo hydrolysis.

Crystalline heterocyclic compound modulates androgen receptor to treat hormone-related conditions.

Engineered exosomes transport CRISPR/Cas9 across the blood-labyrinth barrier to correct MYO7A mutations, reducing toxicity associated with viral vectors.

A topical composition of Zingiber officinale, Alpinia officinarum, and Eruca sativa oils dehydrates Demodex mites.

Imidazole derivatives target CB2 receptors selectively, avoiding central side effects like sedation while providing analgesic benefits.

Factor 1 protein increases capillary density and systolic function while reducing reperfusion injury risk.

Formula IA compounds target specific p38 MAPK isoforms to reduce toxicity while treating inflammatory lung diseases.

A hydrogel composition with permeation enhancers increases therapeutic agent flux across the tympanic membrane.

A minocycline suspension uses a hydrophobic liquid medium to maintain drug stability and reduce systemic exposure.

Switching from U6 to H1 promoter removes guanosine initiation constraints, expanding targetable genome sites and enhancing CRISPR versatility.

Octyl gallate compounds kill or inhibit Bacillus megaterium to reduce drusenoid lesions and inflammation.

Spirocyclic compounds inhibit 11βHSD1 enzyme activity to block cortisone conversion.

Substituted pyridinone compounds inhibit monoacylglycerol acyltransferase 2, reducing fat accumulation and improving insulin sensitivity in obesity treatment.

Adenosine receptor antagonists constrict the pupil to improve near vision while avoiding headaches and ciliary spasm.

4-aminoquinoline derivatives resolve isoform selectivity issues by selectively inhibiting PI3Kδ while sparing other isoforms.

Segmented fused ring compounds with urea moieties activate NAMPT to raise NAD+ levels, addressing insufficient energy homeostasis in metabolic disorders.

Delta-9-THC amino acid ester prodrugs resolve solubility and metabolism bottlenecks to enhance therapeutic efficacy.